{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:10Z","timestamp":1792601650806,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,11,4]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays\u2014overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors\u2014fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, patients had elevated levels of the following biomarkers compared with reference values: fibrinogen, F1+2, D-dimer and parameters of the two global haemostatic assays, that is, ETP and OHP. After 24 weeks we observed a significant reduction in F1+2 (p&lt;0.01), fibrinogen (p&lt;0.01), D-dimer (p&lt;0.01), OHP (p&lt;0.01), ETP (p&lt;0.01), CLT (p&lt;0.01), TAFI (p&lt;0.01) and an increase of OFP (p&lt;0.01). Tocilizumab treatment resulted in the most significant reduction of global haemostatic assays after 24 weeks, that is, a reduction of OHP 73% (p&lt;0.01) compared with certolizumab pegol arm 32% (p&lt;0.01), abatacept arm 24% (p=0.25) or conventional treatment arm 7% (p=0.66).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Newly diagnosed RA patients have enhanced coagulation activation and impaired fibrinolysis as demonstrated by our results. Effective antirheumatic treatments during the first 24 weeks after diagnosis improved this haemostatic imbalance, with prominent effects of biological drugs and especially tocilizumab, compared with conventional treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004838","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T11:35:29Z","timestamp":1735644929000},"page":"e004838","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1698-5647","authenticated-orcid":false,"given":"Bas","family":"Dijkshoorn","sequence":"first","affiliation":[{"name":"Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Hansildaar","sequence":"additional","affiliation":[{"name":"Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Vedder","sequence":"additional","affiliation":[{"name":"Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Soutari","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University Hospital of Iceland, Reykjavik, Iceland"},{"name":"Department of Rheumatology, Centre for Rheumatology Research, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-5546","authenticated-orcid":false,"given":"Kristina","family":"Lend","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, The Netherlands"},{"name":"Department of Medicine, Rheumatology Unit, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Grondal","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital, Reykjavk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Schrumpf","family":"Heiberg","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Danish Hospital for Rheumatic Diseases, S\u00f8nderborg, Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Karolinska Institutet\/Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-5069","authenticated-orcid":false,"given":"Aleksandra","family":"Antovic","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-1934","authenticated-orcid":false,"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"2025090313394539000_10.4.e004838.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200367"},{"key":"2025090313394539000_10.4.e004838.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2025090313394539000_10.4.e004838.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204767"},{"key":"2025090313394539000_10.4.e004838.4","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.jbspin.2020.105122","article-title":"Risk of venous thromboembolism in rheumatoid arthritis","volume":"88","author":"Ketfi","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090313394539000_10.4.e004838.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"2025090313394539000_10.4.e004838.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090313394539000_10.4.e004838.7","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080196"},{"key":"2025090313394539000_10.4.e004838.8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-0038-1648857","article-title":"Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism","volume":"72","author":"Oleksowicz","year":"1994","journal-title":"Thromb Haemost"},{"key":"2025090313394539000_10.4.e004838.9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313394539000_10.4.e004838.10","first-page":"254","article-title":"Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis","volume":"28","author":"Ingegnoli","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313394539000_10.4.e004838.11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2012-eular.2571","article-title":"FRI0114\u2005The effect of combination therapy and prednisolone on haemostatic markers in rheumatoid arthritis: The cobra-light study","volume":"71","author":"van den Oever","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090313394539000_10.4.e004838.12","first-page":"451","article-title":"Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade","volume":"34","author":"Gualtierotti","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313394539000_10.4.e004838.13","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s12325-019-01118-x","article-title":"Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis","volume":"36","author":"Gualtierotti","year":"2019","journal-title":"Adv Ther"},{"key":"2025090313394539000_10.4.e004838.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2003.00462.x"},{"key":"2025090313394539000_10.4.e004838.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1995.tb03642.x"},{"key":"2025090313394539000_10.4.e004838.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04733.x"},{"key":"2025090313394539000_10.4.e004838.17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1265294"},{"key":"2025090313394539000_10.4.e004838.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"2025090313394539000_10.4.e004838.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(01)00332-2"},{"key":"2025090313394539000_10.4.e004838.20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/clinchem\/hvz015","article-title":"The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor","volume":"66","author":"Pruner","year":"2020","journal-title":"Clin Chem"},{"key":"2025090313394539000_10.4.e004838.21","doi-asserted-by":"publisher","DOI":"10.1159\/000071636"},{"key":"2025090313394539000_10.4.e004838.22","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-02-0091"},{"key":"2025090313394539000_10.4.e004838.23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11239-015-1251-1","article-title":"Alterations of the thrombin generation profile in rheumatoid arthritis","volume":"41","author":"Kern","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2025090313394539000_10.4.e004838.24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0043-1775856","article-title":"Thrombin Generation Markers as Predictors of Cancer-Associated Venous Thromboembolism: A Systematic Review","volume":"50","author":"Gyldenholm","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"2025090313394539000_10.4.e004838.25","doi-asserted-by":"crossref","first-page":"10760296221097383","DOI":"10.1177\/10760296221097383","article-title":"Plasminogen activator inhibitor-1, thrombin-antithrombin, and prothrombin fragment F1+2 have higher diagnostic values than D-dimer for venous thromboembolism after TKA","volume":"28","author":"Yang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025090313394539000_10.4.e004838.26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-0037-1612942","article-title":"D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study","volume":"87","author":"Andreescu","year":"2002","journal-title":"Thromb Haemost"},{"key":"2025090313394539000_10.4.e004838.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2492","article-title":"Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis","volume":"346","author":"Schouten","year":"2013","journal-title":"BMJ"},{"key":"2025090313394539000_10.4.e004838.28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2021.10.020","article-title":"Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism","volume":"208","author":"Hansen","year":"2021","journal-title":"Thromb Res"},{"key":"2025090313394539000_10.4.e004838.29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/mr\/road018","article-title":"Clinical disease activity is a major determinant of plasma D-dimer elevation in outpatients with rheumatoid arthritis: A hospital-based cross-sectional study","volume":"34","author":"Mori","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025090313394539000_10.4.e004838.30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/14397595.2018.1428041","article-title":"Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty","volume":"28","author":"Imamura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090313394539000_10.4.e004838.31","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)80476-4"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:39:55Z","timestamp":1756931995000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/rmdopen-2024-004838"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004838","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}